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A series of new amphiphilic pyrrolidines containing dodecyl and oleyl apolar side chains were 
prepared and evaluated for their ability to inhibit the growth of pancreatic ductal adenocarcinoma 
cells in vitro. The new compounds are shown to exhibit anticancer activity at concentrations in 
the M range. 
 






In recent years, several compounds with amphiphilic structure have been proposed as a new type 
of potential anticancer agents due to the lipophilic nature of their lipid chains. Series of such 
compounds isolated from natural sources have indeed shown promising anticancer activities. For 
instance, Ircinamine B, isolated from marine sponge Dactylia,1and Melophlins Q2 isolated from 
Palauan marine sponge are active against mouse leukemia cell lines in the M range. 
Alkylglycerols3 from shark liver also show anticancer activity in vivo in the M range with no 
toxicity on human umbilical vein endothelial cells, the best compounds bearing unsaturated 16 
and 18 carbon alkyl chains. Motuporamine C from a marine Sponge,4 interferes with the 
migration of human breast carcinoma and glioma cells in culture with low toxicity in vitro. 
Sphingosine 4-sulfate5 from the sponge Spirastrella abata shows cytotoxic effects on several 
human tumor cell lines. The glycosyl ceramide, Turbostatin 1,2,3,4,6 from Asian marine mollusk 
Turbo stenogyrus, is active against leukemia cells in the low M range.  
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Notably, synthetic amphiphilic compounds have also shown interesting anticancer properties. 
As shown by Gajate and Mollinedo,7-9 edelfosine  (Figure 1), a lipid analogue of 
lysophosphatidyl-choline induces apoptosis in several tumor cell lines through its lipid ether 
moiety. Once edelfosine is inside the cell, it induces selective apoptosis in cancer cells through 
the activation of the Fas death receptor located on the surface of cells without the participation of 






Other compounds such as Jaspines, having also amphiphilic character by combining a polar 
head (amino and hydroxy moieties) with aliphatic long chains, have shown good anticancer 
activities as well. Among the different diastereoisomeric Jaspines evaluated against human 
alveolar cell lines, Jaspine B (Figure 1) was the most active, showing cytotoxicity at nanomolar 
concentrations in in vitro assays.11  
Due to their amphiphilic nature, glycolipids and their analogues also show therapeutic 
potential. Numerous glycolipid derivatives have been proposed as antibacterial/antiviral 
agents,12,13 cell adhesion mediators,14 and oral drug carriers.15 In the past few years, glycolipids 
have also been proposed as new potential anticancer agents due to the lipophilic nature of their 
aglycones. A variety of synthetic glycolipids have been prepared and their anticancer properties 
evaluated. Thus, oleyl N-acetyl-α- and β-D-glucosaminides and their thioglycosyl analogues 1a 
and 1b (Figure 2) exhibited antimitotic activity on rat glioma (C6) and human lung carcinoma 
(A549) cell cultures in the M range.16,17 Triazologlycolipids 2 showed cytotoxicity against a 






Derivatization of iminosugars with aliphatic side chains has been extensively studied in order to 
improve their biological activity, lipophilicity and bioavailability.19 For instance N-nonyl-1-
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deoxynojirimycin inhibits hepatitis B virus in cell based assays.20 -1-C-Alkyl-1-
deoxynojirimycin derivatives have shown inhibitory activity toward intestinal isomaltase and 
their potency was highly dependent on the alkyl chain length.21 N-alkylated-D-fagomine 
derivatives 3 and N-alkylated hydroxylated pyrrolidine 4 (Figure 3) bearing a long alkyl chain, 
not only presented an improved inhibitory selectivity towards α-D-glucosidase and -L-
fucosidase, respectively, but also exhibited enhanced cytotoxic activities on a panel of cancer 
cell lines compared to their non-alkylated progenitors.22 Other N-alkylated pyrrolidine 
derivatives such as 523 and 624,25 presented interesting inhibition against N-





5-O-Alkyl 1,4-dideoxy-1,4-imino-D-ribitols bearing different long alkyl chains 7-12 (Figure 3) 
were evaluated as enzyme inhibitors and for their toxicity on solid and hematological 
malignancies showing activities in the M range.26,27 Even though these compounds are not 
inhibitors of α-mannosidases, they show promising cytotoxicity on solid and hematological 
malignancies, their activity depending on the length of the alkyl side chain. The oleyl derivative 
9 and its C-18 analogues, linoleyl 10, linolenyl 11 and octadecyl 12, exhibited the most potent 
anti-cancer activity, with oleyl-conjugate 9 being the most efficient in killing tumor cells. These 
results indicated that the side chain and the number and position of the unsaturations play a role 
in determining the biological properties of this class of compounds. The anticancer activities 
increased with the length of the alkyl chain, in accordance with the reported data for other 
iminosugars22 and with the hypothesis that a higher lipophilicity would facilitate compound 
transport through the cell membrane. 
Compound 9 was chosen as representative of the new class of compounds because of its 
interesting anticancer activities against breast, lung, prostate cancer, and glioblastoma cells in the 
M range (IC50 between 2 and 21 M).26,27  
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Results and Discussion    
 
The promising results shown by compound 9 and derivatives, prompted us to explore further 
structural variations in order to improve their anticancer properties, in particular in pancreatic 
cancer cell lines. Thus, different series of compounds bearing amphiphilic character were 
prepared for structure-activity relationship studies by combining polyhydroxylated pyrrolidines 
with 2-fatty-alkyl moieties.  
We report herein the synthesis of a series of this type of compounds starting from different 
sugars as source of chirality and the results of their evaluation in terms of toxicity in pancreatic 
cancer cell lines. The structural variations of the new compounds are shown in Figure 4. The 
diversity at the new structures will allow us to examine the role of different configurations at the 
stereogenic centers, the type of linker (X), the distance between the side chain and the 
pyrrolidine skeleton and the role of different functionalities at the nitrogen atom on their 




Figure 4. Structural variations for new amphiphilic pyrrolidine-3,4-diol derivatives. 
 
Thus, compound 19 was prepared from D-ribose as outlined in Scheme 1. Starting from the 
known D-ribose derivative 13,28 reaction with ethyl triphenylphosphoranylidene acetate in 
dichloromethane  at reflux afforded a mixture of alkenes 14 and 15 in 86% yield and a ratio E:Z 
1:3.6. The stereoselectivity in the Wittig reaction was in accordance with that described in the 
literature for other ribo-lactols.29 Mesylation of the free OH group in both alkenes followed by 
treatment with ammonia in ethanol led to pyrrolidine 16 as unique product (94% yield), through 
tandem conjugate addition-internal SN2 displacement. Reductive amination with butanal, ester 
hydrolysis and amide coupling with oleyl amine in the presence of PyBOP and DIPEA afforded 
compound 18 in 30% yield (two last steps). Deprotection with TBAF led to pyrrolidine 19 in 
quantitative yield. Attempts to deprotect 19 with cold TFA aq. were unsuccessful. The 
preparation of other acetonide protected pyrrolidines with the same configuration have been 
reported.30  
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Scheme 1. Synthesis of 19. 
 
The effect of a triazole linker between the pyrrolidine skeleton and the side chain was also 
studied. These compounds were prepared by click chemistry upon reaction of the corresponding 




Figure 5. Retrosynthesis for triazole-pyrrolidine compounds. 
 
Differently configurated pyrrolidine azides were obtained from D-mannose, D-gulono--
lactone and D-arabinose (Figure 5). 
The preparation of the azido-pyrrolidines is outlined in Scheme 2. Starting from known 
aldehyde 20,31 reduction and tosylation gave derivative 21, which after displacement with 
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sodium azide in DMF furnished azido derivative 22. Similarly, derivative 25 was obtained by 
azido displacement of the corresponding tosyl derivative 2432, obtained through oxidation, 
reduction and tosylation of known diol 23.33 Derivative 28 was prepared from pyrrolidine ester 





Scheme 2. Synthesis of azido-pyrrolidines. 
 
The preparation of these azido derivatives requires benzyloxycarbonyl as N protecting group. 
The use of other carbamates as protecting groups for the preparation of the azido pyrrolidines 
gave unexpected results. Thus, tosylation of Boc-protected alcohol 29 did not lead to the 
corresponding tosyl derivative as expected. Instead, we mostly obtained cyclic carbamate 30 
(Scheme 3) as confirmed by its spectral data. The 1H- and 13C NMR spectra of 30 did not show 
the typical signals for the tosyl and tert-butyl groups. However, a signal at 152.9 ppm was 
observed in the 13C NMR spectra, corresponding to the carbonyl group of the carbamate. 
 
Scheme 3. Participation of the N-protecting group. 
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The formation of cyclic carbamate 30 depends on the protecting group used in the 
introduction of the azide group at C-1’ of the pyrrolidine. Boc protecting group as well as Fmoc 
exhibit a hydrogen atom at the β position with respect to the oxygen atom, which is not the case 
in the Cbz group. Under mild basic conditions, the H at  position is released with the 
concomitant displacement of the leaving group, promoting the formation of the cyclic carbamate, 




Scheme 4. Participation of carbamates on leaving group departure. 
 
Compounds bearing a triazole moiety were prepared by copper-catalyzed dipolar 
cycloaddition35-37 of pyrrolidine azides (22, 25 and 28) and tetradec-1-yne in the presence of CuI 
and DIPEA. Subsequent deprotection reactions led to derivatives 31, 32 and 33 in good overall 
yields, and their structures were confirmed by NMR and HRMS spectra (Scheme 5). 
 
Scheme 5. Preparation of triazole derivatives. 
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Biological evaluation. The cytotoxic activity of the new amphiphilic derivatives has been 
evaluated on the pancreatic cancer cell lines MiaPaCa2 and PK9. The results are summarized in 
Table 1. They all exhibited antiproliferative activity in the M range. 
Although undoubtedly much research needs to be done in this area, the results shown here 
indicate that the amphiphilic compounds combining unsaturated alkyl chains and iminoalditols 
of defined configurations might be of interest for the definition of new anticancer agents to be 
used in the treatment of pancreatic cancer.  
 
Table 1. IC50 of analogues of 9 toward pancreatic cancer cell lines. IC50 (M) 
 Compounds 19 31 32 33 
Cell line 
MiaPaCa2 3.6 21 35 14 
PK9 17 19 45 16 
 
 
Experimental Section  
    
General. Optical rotations were measured in a 1.0 cm or 1.0 dm tube with a Perkin–Elmer 
241MC spectropolarimeter. 1H and 13C NMR spectra were obtained for solutions in CDCl3, 
[d6]DMSO and CD3OD; J values are given in Hz and δ in ppm. All the assignments were 
confirmed by two-dimensional NMR experiments (COSY and HSQC). The LSI mass spectra 
were obtained using glycerol or 3-nitrobenzyl alcohol as the matrix. NMR and Mass spectra 
were registered in CITIUS (University of Seville). TLC was performed over silica gel HF254 
(Merck), with detection by UV light charring with ninhydrin or with Pancaldi reagent 
[(NH4)6MoO4, Ce(SO4)2, H2SO4, H2O]. Silica gel 60 (Merck, 63-200 m) was used for 
preparative chromatography.  
 
(E)- and (Z)-Ethyl  7-O-tert-butyldiphenylsilyl-2,3-dideoxy-4,5-O-isopropylidene-D-ribohept 
-2-enoate (14 and 15). Ethoxycarbonyltriphenylmethylenephosphorane (7 g, 20.1 mmol) was 
added to a solution of 1328 (3.75 g, 8.76 mmol) in dry CH2Cl2 (80 mL) and the mixture was 
heated at reflux for 6 h. After evaporation of the solvent, the residue was purified by column 
chromatography (ethyl acetate/petroleum ether 1:10) to afford 14 and 15 as oils (3.74 g, 86%, 
14:15 = 1:3.6). Data for 14:  29Dα  +9.2 (c 1.24, CH2Cl2); IR (ν cm-1) 3462, 2931, 2857, 1718, 
1657, 1428 , 1110, 1059, 822, 740, 701, 614. 1H NMR (300 MHz, CDCl3,  ppm, J Hz)  7.69-
7.64 (m, 4H, H-arom.), 7.46-7.36 (m, 6H, H-arom.), 7.12 (dd, 1H, J3,2 15.6, J3,4 4.9, H-3), 6.14 
(dd, 1H, J2,4 1.6, H-2), 4.86 (m, 1H, H-4), 4.25-4.18 (m, 3H, H-5, CH2CH3), 3.84 (dd, 1H, J7a,7b 
10.4, J7a,6 3.3, H-7a), 3.76 (dd, 1H, J7b,6 5.5, H-7b), 3.63 (m, 1H, H-6), 2.58 (d, 1H, JOH,6 5.7, 
OH), 1.41, 1.35 (2s, 3H each, C(CH3)2), 1.30 (t, 3H, JH,H 7.2, CH2CH3), 1.07 (s, 9H, C(CH3)3). 
13C NMR  (75.4 MHz, CDCl3,  ppm)  166.2 (COOEt), 143.8 (C-3), 135.6, 132.8, 129.8, 127.7 
(C-arom.), 122.3 (C-2), 109.4 (C(CH3)2), 77.4 (C-5), 76.8 (C-4), 69.8 (C-6), 65.2 (C-7), 60.4 
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(CH2CH3), 27.6 (C(CH3)2), 26.8 (C(CH3)3), 25.3 (C(CH3)2), 19.3 (C(CH3)3), 14.2 (CH2CH3). 
CIMS m/z 499 [1%, (M+H)+]. HRCIMS m/z found 499.2512, calc. for C28H39O6Si: 499.2516.  
Data for 15:  29Dα  +76.2 (c 1.05, CH2Cl2);  IR  (ν cm-1) 2931, 2857, 1716, 1698, 1427, 1380, 
1190, 1055, 869, 822, 701, 615. 1H NMR (300 MHz, CDCl3,  ppm, J Hz)  7.68-7.66 (m, 4H, 
H-arom.), 7.45-7.35 (m, 6H, H-arom.), 6.23 (dd, 1H, J3,2 11.7, J3,4 8.4, H-3), 5.94 (dd, 1H, J2,4 
1.1, H-2), 5.74 (m, 1H, H-4), 4.38 (dd, 1H, J5,4 8.1, J5,6 6.3, H-5), 4.19 (q, 2H, JH,H 6.9, 
CH2CH3), 3.84-3.75 (m, 2H, H-7a, H-7b), 3.66 (m, 1H, H-6), 2.80 (d, 1H, JOH,6 4.5, OH), 1.38, 
1.35 (2s, 3H each, C(CH3)2), 1.30 (t, 3H, CH2CH3), 1.06 (s, 9H, C(CH3)3). 
13C NMR  (75.4 
MHz, CDCl3,  ppm)  166.1 (COOEt), 144.6 (C-3), 135.6, 133.2, 129.7, 127.7 (C-arom.), 122.2 
(C-2), 109.1 (C(CH3)2), 78.1 (C-5), 73.9 (C-4), 70.3 (C-6), 65.1 (C-7), 60.6 (CH2CH3), 27.8 
(C(CH3)2), 26.8 (C(CH3)3), 25.4 (C(CH3)2), 19.3 (C(CH3)3), 14.2 (CH2CH3). CIMS  m/z 499 
[1%, (M+H)+]. HRCIMS m/z found 499.2498, calc. for C28H39O6Si: 499.2516. 
Ethyl 7-O-tert-butyldiphenylsilyl-2,3,6-trideoxy-3,6-imino-4,5-O-isopropylidene-L-galacto- 
heptanoate ((2S,3R,4S,5R)-2-tert-butyldiphenylsilyloxymethyl-5-ethoxycarbonylmethyl-3,4-
O-isopropylidene- pyrrolidine-3,4-diol) (16). A solution of 14 and 15 (2.22 g, 4.45 mmol) in 
dry CH2Cl2 (10 mL) was added dropwise to a stirred solution of MsCl (1.2 mL, 16.0 mmol) in 
dry pyridine (4 mL) cooled to 0 ºC. After stirring at r.t. overnight, the mixture was cooled to 0 
ºC, H2O (5 mL) was added and the reaction stirred for 15 min at r.t. The solvent was then 
evaporated, the crude diluted with dichloromethane and washed with H2O and brine. The organic 
phase was dried, filtered and concentrated. The residue was dissolved in absolute EtOH (45 mL), 
cooled to 0 ºC and saturated with NH3. After 4 days at r.t., the solvent was evaporated and the 
residue was treated with NH4OH (25%, 30 mL) and extracted with CH2Cl2 (5x30 mL). The 
organic phase was washed with satd. aq. sol. of NaHCO3 (30 mL) and H2O until neutral pH, 
dried (Na2SO4), filtered and concentrated. The residue was purified by column chromatography 
(AcOEt:petroleum ether (1:6), Et3N (1%)) to give pure 16 as an oil (2.09 g, 94%).  26Dα  +12.3 (c 
1.25, CH2Cl2); IR (ν cm
-1) 2930, 2857, 1731, 1108, 1091, 822, 739, 701, 615. 1H NMR (300 
MHz, CDCl3,  ppm, J Hz)  7.72-7.68 (m, 4H, H-arom.), 7.41-7.34 (m, 6H, H-arom.), 4.63 (dd, 
1H, J5,4 5.7, J5,6 4.1, H-5), 4.60 (dd, 1H, J4,3 4.2, H-4), 4.15 (m, 2H, CH2CH3), 3.90 (dd, 1H, J7a,7b 
10.4, J7a,6 7.1, H-7a), 3.83 (dd, 1H, J7b,6 6.7, H-7b), 3.17 (ddd, 1H, J3,2b 7.6, J3,2a 6.4, H-3), 3.02 
(m, 1H, H-6), 2.66 (dd, 1H, 2J2a,2b 17.0, H-2a), 2.59 (dd, 1H, H-2b), 1.81 (br s, 1H, NH), 1.39, 
1.29 (2s, 3H each, C(CH3)2), 1.26 (t, 3H, CH2CH3), 1.06 (s, 9H, C(CH3)3). 
13C NMR  (75.4 
MHz, CDCl3,  ppm)  172.2 (COOEt), 135.7, 135.6, 133.7, 133.6, 129.5, 127.6, 127.5 (C-
arom.), 111.0 (C(CH3)2), 81.3 (C-4), 80.6 (C-5), 63.6 (C-6), 62.5 (C-7), 60.4 (CH2CH3), 58.1 (C-
3), 34.1 (C-2), 26.8 (C(CH3)3), 25.7, 24.5 (C(CH3)2), 19.2 (C(CH3)3), 14.2 (CH2CH3). CIMS m/z 
497 [1%, (M)+], 440 [50%, (M-tBu)+]. HRCIMS  m/z found 497.2591, calc. for C28H39NO5Si: 
497.2598. 
(2S,3R,4S,5R)-N-Butyl-2-tert-butyldiphenylsilyloxymethyl-5-ethoxycarbonylmethyl-3,4-O-
isopropylidene-pyrrolidine-3,4-diol (17). Butanal (0.3 mL, 3.38 mmol) and NaBH(OAc)3 (752 
mg, 3.55 mmol) were added to a solution of 16 (840 mg, 1.69 mmol) in 1,2-dichloroethane (10 
mL). The reaction mixture was stirred overnight at r.t. Then, aq. sat. sol. of NaHCO3 was added 
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and the mixture extracted with CH2Cl2. The organic phases were dried (Na2SO4) and evaporated 
in vacuo. Purification of the residue by column chromatography (AcOEt:petroleum ether 1:10) 
afforded 17 as an oil (825 mg, 88%).  29Dα +1.9 (c 1.15, CH2Cl2); IR  (ν cm-1) 2931, 2857, 1732, 
1110, 1087, 823, 738, 701, 613. 1H NMR (300 MHz, CDCl3,  ppm, J Hz)  7.73-7.68 (m, 4H, 
H-arom.), 7.42-7.34 (m, 6H, H-arom.), 4.64-4.62 (m, 2H, H-4, H-3), 4.15 (qd, 2H, 3JH,H 7.1, J 
1.4, OCH2CH3), 3.98 (dd, 1H, J1’a,1’b 10.2, J1’a,2 6.8, H-1’a), 3.75 (dd, 1H, J1’b,2 5.4, H-1’b), 2.85 
(m, 1H, H-5), 2.72-2.63 (m, 2H, H-2, H-1’’a), 2.61-2.40 (m, 3H, H-1’’b, CH2-N), 1.39, 1.29 (2s, 
3H each, C(CH3)2), 1.25 (t, 3H, OCH2CH3), 1.24-1.09 (m, 4H, CH2CH2), 1.05 (s, 9H, C(CH3)3), 
0.83 (t, 3H, 3JH,H 7.2, CH3). 
13C NMR  (75.4 MHz, CDCl3,  ppm)  172.4 (COOEt), 135.7, 
135.6, 133.9, 133.6, 129.5, 127.6, 127.5 (C-arom.), 110.8 (C(CH3)2), 79.4, 79.1 (C-4, C-3), 67.7 
(C-2), 62.7, 62.5 (C-1’, C-5), 60.3 (OCH2CH3), 49.5 (C-1’’), 33.2 (CH2-N), 27.1 (CH2), 26.8 
(C(CH3)3), 26.0, 25.7 (C(CH3)2), 20.7 (CH2), 19.2 (C(CH3)3), 14.2, 14.0 (OCH2CH3, CH2CH3). 
CIMS m/z 554 [15%, (M+H)+]. HRCIMS m/z found 554.3283, calc. for C32H48NO5Si: 554.3302.  
(2S,3R,4S,5R)-N-Butyl-2-tert-butyldiphenylsilyloxymethyl-3,4-O-isopropylidene-5-oleyl-
carbamoylmethyl pyrrolidine-3,4-diol (18). A solution of 17 (119 mg, 0.23 mmol) in 
EtOH:1M NaOH (1:1, 3 mL) was stirred for 2 h at r.t. Then, the mixture was neutralized with 
IRA-120 (H+) resin, filtered and concentrated. The residue thus obtained was dissolved in DMF 
(2 mL) and oleyl amine (67 mg, 0.25 mmol), DIPEA (118 L, 0.69 mmol) and PyBOP (130 mg, 
0.25 mmol) were added. After stirring at r.t. overnight, the mixture was evaporated to dryness 
and the residue was dissolved in CH2Cl2 and washed with 1M HCl, sat. aq. soln. of NaHCO3 and 
sat. aq. soln. of NaCl.  The dried organic phase (MgSO4) was purified by chromatography over 
silica gel (AcOEt:petroleum ether 1:3) to give 18 as an oil (53 mg, 30%).  29Dα -1.7 (c 1.05, 
CH2Cl2); IR (ν cm
-1) 3299, 2921, 2852, 1643, 1110, 1092, 823, 738, 701, 614. 1H NMR (300 
MHz, CDCl3,  ppm, J Hz)  7.73-7.67 (m, 4H, H-arom.), 7.42-7.35 (m, 6H, H-arom.), 6.56 (br 
t, 1H, NH), 5.38-5.32 (m, 2H, CH=CH), 4.62 (dd, 1H, J 6.5, J 4.8, H-3), 4.50 (br dd, 1H, H-4), 
3.97 (dd, 1H, 2J1’a,1’b 10.0, J1’a,2 7.0, H-1’a), 3.76 (dd, 1H, J1’b,2 5.0, H-1’b), 3.20 (q, 2H, JH,H 6.4, 
CH2-NH), 2.83 (m, 1H, H-5), 2.70 (m, 1H, H-2), 2.63-2.35 (m, 4H, H-1’’a, H-1’’b, CH2-N), 
2.02-1.98 (m, 4H, CH2-CH=CH-CH2), 1.39 (s, 3H, C(CH3)2), 1.48-1.09 (m, 31H, 14CH2, 
C(CH3)2), 1.05 (s, 9H, C(CH3)3), 0.88 (t, 3H, JH,H 6.3, CH3), 0.83 (t, 3H, JH,H 7.2, CH3). 
13C 
NMR  (75.4 MHz, CDCl3,  ppm)  171.3 (C=O), 135.7, 135.5, 133.7, 133.5 (C-arom.), 129.9, 
129.7 (CH=CH), 129.6, 129.5, 127.6, 127.5 (C-arom.), 110.7 (C(CH3)2), 79.2 (C-4), 79.0 (C-3), 
67.6 (C-2), 63.4 (C-5), 62.5 (C-1’), 49.4 (C-1’’), 35.2 (CH2-N), 32.6 (CH2), 31.9 (CH2), 29.7-
29.2 (CH2), 27.2, 27.1 (CH2), 26.7 (C(CH3)3), 25.7, 25.0 (C(CH3)2), 22.6 (CH2), 20.6 (CH2), 19.1 
(C(CH3)3), 14.1, 14.0 (2CH3). CIMS m/z 775 [100%, (M+H)
+]. HRCIMS m/z found 775.5804, 
calc. for C48H79N2O4Si: 775.5809.  
(2S,3R,4S,5R)-N-Butyl-2-hydroxymethyl-3,4-O-isopropylidene-5-oleylcarbamoylmethyl 
pyrrolidine-3,4-diol (19). TBAF (1 M  in THF, 0.25 mL) was added to a solution of 18 (59.4 
mg, 0.071 mmol) in THF (1 mL). After stirring at r.t. for 5 h, the solvent was evaporated and the 
residue purified by chromatography column over  silica gel (ether/acetone 50:1) to afford 19 as 
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an oil (38 mg, quant.).  28Dα -10.6 (c 1.04, CH2Cl2); IR (ν cm-1)  3306 (OH, NH), 2924, 2855, 
1648 (C=O), 1458, 1206, 1043, 713. 1H NMR (300 MHz, CDCl3,  ppm, J Hz)  6.54 (br t, 1H, 
NH), 5.39-5.32 (m, 2H, CH=CH), 4.69 (dd, 1H, J 5.1, J 6.3, H-3 or H-4), 4.58 (dd, 1H, J 5.1, J 
6.0, H-3 or H-4), 3.94 (dd, 1H, 2J1’a,1’b 11.7, J1’a,2 2.5, H-1’a), 3.82 (dd, 1H, J1’b,2 5.8, H-1’b), 
3.25-3.18 (m, 2H, CH2-NH), 3.02 (br s, 1H, H-5), 2.68-2.45 (m, 5H, H-2, H-1’’a, H-1’’b, CH2-
N), 2.07-1.91 (m, 4H, CH2-CH=CH-CH2), 1.49 (s, 3H, C(CH3)2), 1.36-1.22 (m, 36H, 14CH2, 
C(CH3)2), 0.94-0.83 (m, 6H, 2 CH3). 
13C NMR  (75.4 MHz, CDCl3,  ppm)  171.0 (C=O), 
130.0, 129.7 (CH=CH), 111.2 (C(CH3)2), 80.3, 79.4 (C-3, C-4), 65.7 (C-2), 62.7 (C-5), 59.9 (C-
1’), 48.8 (C-1’’), 39.4 (CH2-NH), 31.9 (CH2-N), 29.7-20.7 (16CH2, C(CH3)2), 14.1, 13.9 (2CH3). 
CIMS m/z 537 [100%, (M+H)+]. HRCIMS m/z found 537.4637, calc. for C32H61N2 O4: 537.4631. 
(2S,3S,4R,5S)-N-Benzyloxycarbonyl-2-tosyloxymethyl-3,4-O-isopropylidene-5-methyl-
pyrrolidine-3,4- diol (21). NaBH4 (0.43 g, 4.75 mmol) was added to a solution of 20
31 (735 mg, 
2.30 mmol) in MeOH (11 mL), and the mixture stirred at r.t. for 20 min. Then, AcOH (0.1 mL) 
was added and the mixture subsequently diluted with AcOEt and washed with sat. aq. soln. of 
NaHCO3. The organic phases were dried, filtered and concentrated. The residue was purified by 
chromatography column over  silica gel (AcOEt:petroleum ether 1:2) to afford the corresponding 
alcohol (0.63 g, 85%).  To a 0 ºC solution of the alcohol (383 mg, 1.19 mmol) in dry pyridine (10 
mL) was slowly added TsCl (0.69 g, 3.56 mmol). After stirring at r.t for 4.5 h, the mixture was 
cooled to 0 ºC, water was slowly added (0.5 mL), and the mixture was allowed to warm to r.t. 
Solvent was then removed, and the residue was diluted with AcOEt, washed with HCl (1N), sat. 
aq. soln. of NaHCO3 and brine, dried, filtered, and concentrated. Purification by chromatography 
column (AcOEt:cyclohexane 1:4) afforded 21 as an oil (414 mg, 73%).  
28
Dα  + 18.2  (c 0.51, 
CH2Cl2). IR νmax  2986 , 2938, 1698 (C=O), 1356 (S=O), 1175, 814 cm
-1. 1H NMR (300 MHz, 
DMSO-d6, 363 K, δ ppm) δ 7.78-7.73 (m, 2H, H-arom. of Ts), 7.47-7.44 (m, 2H, H-arom. of Ts), 
7.39-7.28 (m, 5H, H-arom.), 5.09 (d, 1H, 2JH,H 12.7, CH2 of Cbz), 5.04 (d, 1H, CH2 of Cbz), 4.60 
(dd, 1H, J3,4 5.7, J3,2 1.5, H-3), 4.38 (dd, 1H, J4,5 1.4, H-4), 4.19 (dd, 1H, 
2J1’a,1’b  9.8, J1’a,2  3.7, H-
1’a ), 4.09 (dd, 1H, J1’b,2  5.9, H-1’b), 4.05 (m, 1H, H-2), 3.98  (qd, 1H, J5,Me 6.9, H-5), 2.42 (s, 
3H, Me of Ts ), 1.33, 1.25 (2s, 3H each, C(CH3)2), 1.13 (d, 3H, Me). 
13C NMR  (75.4 MHz, 
DMSO-d6, 363 K, δ ppm)  δ 153.3 (C=O of Cbz), 144.6, 136.2, 132.1, 129.6, 127.8, 127.3, 
127.0, 126.7, 125.1 (C-arom.), 110.8 (C(CH3)2), 84.2 (C-4), 80.5 (C-3), 68.4 (C-1’), 65.9 (CH2 of 
Cbz), 62.8 (C-2), 59.6 (C-5), 26.6, 24.6 (C(CH3)2), 20.5 (Me of Ts), 18.2 (Me). CIMS m/z 476 
[1%, (M+H)+], 340 [10%, (M-Cbz+H)+]. HRCIMS  m/z found 476.1736, calcd. for C24H30NO7S 
[M+H]+: 476.1743. 
(2S,3S,4R,5S)-N-Benzyloxycarbonyl-2-azidomethyl-3,4-O-isopropylidene-5-methyl-
pyrrolidine-3,4-diol (22). NaN3 (137 mg, 2.18 mmol) was added to a solution of 21 (414 mg, 
0.87 mmol) in DMF (7.5 mL). After heating at 70 ºC for 3 h, the solvent was evaporated and the 
residue diluted with CH2Cl2 and washed with water and brine. The organic phase was dried, 
filtered, and concentrated. Purification by chromatography column (AcOEt:cyclohexane 1:6) 
afforded 22 as an oil (276 mg, 92%).  
28
Dα  + 60.4 (c 0.55, CH2Cl2). IR νmax  2986, 2938, 2103 
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(N3), 1693 (C=O), 1403, 1210, 1026, 697 cm
-1. 1H NMR (300 MHz, DMSO-d6, 363 K, δ ppm) δ 
7.39-7.28 (m, 5H, H-arom.), 5.14 (d, 1H, 2JH,H 12.5, CH2 of Cbz), 5.08 (d, 1H, CH2 of Cbz), 4.68 
(t, 1H, J4, 3= J4,5   6.2, H-4),  4.56 (dd, 1H, J3,2 1.0, H-3), 3.99 (m, 1H, H-2), 3.90 (q, 1H, J5,Me 6.4, 
H-5),  3.66 (dd, 1H, 2J1’a,1’b  12.8, J1’a,2   6.0, H-1’a ), 3.53 (dd,  1H,  J1’b,2  3.5, H-1’b), 1.40, 1.30 
(2s, 3H each, C(CH3)2,) 1.29 (d, 3H, Me). 
13C NMR (75.4 MHz, DMSO-d6, 363 K, δ ppm) δ 
153.6 (C=O of Cbz), 136.2, 127.8, 127.4, 127.2 (C-arom.), 110.4 (C(CH3)2), 80.7 (C-3), 79.4 (C-
4), 65.8 (CH2 of Cbz), 61.8 (C-2), 56.6 (C-5), 50.5 (C-1’), 25.4 , 24.4 (C(CH3)2), 14.6 (Me). 
CIMS m/z 347 [2%, (M+H)+], 290 [26%, (M-CH2N3)




(25).  A solution of NaIO4 (3.0 g, 14.0 mmol) in H2O (40 mL) was added dropwise to a 0 ºC 
solution of diol 2333
 
(2.36 g, 7.0 mmol) in THF (35 mL). After 45 min., THF was evaporated and 
the mixture extracted with CH2Cl2. The organic phases were washed with water, sat. aq. soln. of 
NaHCO3 and brine, dried, filtered and concentrated. The aldehyde obtained was then dissolved 
in MeOH (40 mL), cooled to 0 ºC and NaBH4 (260 mg, 6.8 mmol) was added. After 30 min., the 
mixture was diluted with CH2Cl2, and washed with water and brine. The organic phase was 
dried, filtered and concentrated. The crude alcohol so-obtained was then dissolved in dry 
pyridine (25 mL), TsCl (4.34 g, 22.8 mmol) was added and the mixture stirred at 20 oC for 12 h. 
Water was added dropwise under stirring and the mixture evaporated to dryness. The residue was 
dissolved in CH2Cl2 and washed with water and brine. The organic phase was dried, filtered and 
concentrated. The tosylate ester 2432 so-obtained was dissolved in DMF (30 mL) and NaN3 (0.93 
g, 14.2 mmol) was added. After heating to 50 ºC for 2.5 h, the solvent was evaporated and the 
residue diluted with CH2Cl2 and washed with water and brine. The organic phase was dried, 
filtered, and concentrated. Purification by chromatography column (AcOEt:cyclohexane 1:1) 
afforded 25 (1.68 g, 72 %, 4 steps).  
27
Dα = -46.0 (c 0.87, CH2Cl2).  IR νmax  2996, 2938, 2103 
(N3), 1698 (C=O), 1350, 1043, 769 cm
-1. 1H NMR  (300 MHz, DMSO-d6, 363 K)  δ 7.33-7.29 
(m, 5H, H-arom.), 5.12 (s, 2H, CH2 of Cbz), 4.77 (m, 1H, H-4), 4.57 (dd, 1H, J3,4 6.0,  J3,2 0.6, 
H-3), 4.07 (br. t, 1H, J2,1’a 5.7,  H-2), 3.74 (dd, 1H, J5a,4 1.2, 
2J5a,5b 12.9, H-5a), 3.56-3.44 (m, 3H, 
H-5b, H-1’a, H-1’b), 1.32, 1.26 (2s, 3H each, C(CH3)2). 
13C NMR (75.4 MHz, DMSO-d6, 363 K) 
δ 153.7 (C=O), 136.4, 127.8, 127.3, 126.8 (C-arom.), 110.6 (C(CH3)2), 81.7 (C-3), 78.2 (C-4), 
65.9 (CH2 of Cbz), 62.6 (C-2), 51.4 (C-5), 50.3 (C-1’), 26.3 (C(CH3)2), 24.4 (C(CH3)2). 
HRCIMS: calculated for C16H21N4O4:  333.1563, found 333.1570 [M+H]
+. 
 (2R,3S,4R)-N-Benzyloxycarbonyl-2-azidoethyl-3,4-O-isopropylidene-pyrrolidine-3,4-diol 
(28). NaHCO3  (155 mg, 1.84 mmol) and CbzCl (310 μL, 2.02 mmol) were added to a solution 
of 26 34
 
 (421.7 mg, 1.84 mmol) in EtOH:H2O (1:1, 10 mL), and the mixture stirred at r.t for 3 h. 
Then, it was poured into a sat. aq. soln. of NaHCO3 and extracted with AcOEt. The dried organic 
phase was evaporated and the obtained residue was purified by column chromatography over 
silica gel (AcOEt:cyclohexane, 1:3) affording the corresponding N-protected pyrrolidine (594.9 
mg, 97%). Then, to a cooled (-10 ºC) suspension of LiAlH4 (35 mg, 0.91 mmol) in anh. THF (3 
mL), the protected pyrrolidine (274 mg, 0.756 mmol) in THF (5 mL) was added. After 10 min., 
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sat. aq. soln. of Na2SO4 (20 mL) was added dropwise and the mixture extracted with AcOEt. The 
dried organic phase was evaporated and the obtained residue was purified by column 
chromatography over silica gel (toluene:acetone, 5:1) to afford the corresponding hydroxyethyl 
pyrrolidine  27 (171 mg, 70%). To a solution of this compound (221 mg, 0.69 mmol) in anh. 
CH2Cl2 (4 mL), anh. pyridine (3 mL) and MsCl (160 µL, 2.06 mmol) were added. After 1.5 h, 
the reaction was quenched with water (4 mL) and evaporated. The residue was diluted with 
CH2Cl2, washed with water and brine, dried, filtered and concentrated. The crude product was 
then dissolved in anh. DMF (5 mL) and NaN3 (135 mg, 2.06 mmol) was then added. The mixture 
was heated at 70 ºC for 3 h and then evaporated. The residue was dissolved in CH2Cl2, washed 
with water and brine, dried, filtered and concentrated. The resulting residue was purified by 
column chromatography (AcOEt:cyclohexane 1:4) to give pure 28 as an oil (144.8 mg, 61%, 2 
steps).  28Dα -53.6 (c 1.04, CH2Cl2); IR (ν cm-1)  2981, 2937, 2093 (N3), 1700 (C=O), 1410, 1206, 
1084, 747.  1H-NMR (300 MHz, DMSO-d6, 363 K, δ ppm, J Hz) 7.37-7.30 (m, 5H, H-arom.), 
5.01 (s, 2H, CH2 of Cbz), 4.79-4.72 (m, 2H, H-4, H-3), 3.96-3.81 (m, 1H, H-2), 3.79-3.73 (m, 
1H, H-5a), 3.41-3.28 (m, 3H, H-2’, H-5b), 2.16-2.05 (m, 1H, H-1’a), 2.01-1.92 (m, 1H, H-1’b), 
1.44, 1.30 (2s, 3H each, -C(CH3)2). 
13C-NMR (75.4 MHz, DMSO-d6, 363 K, δ ppm) 154.2 
(C=O), 136.5, 128.0, 127.4, 127.1 (C-arom.), 111.5 (-C(CH3)2), 79.2, 77.0 (C-3, C-4), 65.9 (CH2 
of Cbz), 57.2 (C-2), 50.4 (C-5), 48.0 (C-2’), 28.0 (C-1’), 25.9 (-C(CH3)2), 24.6 (-C(CH3)2). 
CIMS m/z 347 [11%, (M+H)+]. HRCIMS m/z found 347.1712, calc. for C17H23N4 O4: 347.1719.  
(2S,3S,4R,5S)-2-[(4’’-Dodecyl)-1H-1,2,3-triazole-1-yl)methyl)]-5-methylpyrrolidine-3,4-diol 
hydrochloride (31). Tetradec-1-yne (43 μL, 0.21 mmol), DIPEA (41 μL, 0.42 mmol) and CuI (7 
mg, 0.03 mmol) were added to a solution of 22 (39.6 mg, 0.114 mmol) in toluene (1 mL). The 
mixture was stirred at r.t. for 20 h and then, a sat. aq. soln. of NaHCO3 was added and extracted 
with AcOEt. The organic phases were dried, filtered and concentrated. Purification by 
chromatography column (Et2O:cyclohexane 2:1) afforded the triazole derivative (58.3 mg, 95%). 
 27Dα +80.1 (c 0.96, CH2Cl2). IR νmax  2918, 2849, 1726 (C=O), 1201, 1027, 738 cm-1. 1H NMR 
(300 MHz, DMSO-d6, 363 K, δ ppm) δ 7.54 (s, 1H, H-5’’), 7.41-7.32 (m, 5H, H-arom.), 5.13 (d, 
1H, 2JH,H 12.3, CH2 of Cbz), 5.07 (d, 1H, CH2 of Cbz), 4.74 (d, 1H, J3,4 6.0, H-3), 4.62 (dd, 1H, 
J1’a,2 6.3, 
2J1’a,1,b 13.8, H-1’a), 4.52 (dd, 1H, J1’b,2 3.6, H-1’b), 4.34 (t, 1H, J4,5 6.0, H-4), 4.27 (m, 
1H, H-2), 3.38 (q, 1H, J5,Me 6.0, H-5), 2.60 (t, 2H, JH,H 7.5, -CH2(CH2)10CH3), 1.58 (q, 2H, JH,H 
6.3, -CH2CH2(CH2)9CH3), 1.37-1.23 (m, 27H, -CH2CH2(CH2)9CH3, -C(CH3)2, Me), 0.87 (t, 3H, 
JH,H 7.2, -(CH2)11CH3). 
13C NMR (75.4 MHz, DMSO-d6, 363 K, δ ppm) δ 153.6 (C=O), 146.8 
(C-4’’), 136.2, 127.8, 127.4, 127.3 (C-arom.), 122.0 (C-5’’), 110.3 (C(CH3)2), 80.2 (C-4), 79.4 
(C-3), 65.8 (CH2 of Cbz), 62.4 (C-2), 56.3 (C-5), 48.4 (C-1’), 30.7, 28.4, 28.3, 28.2, 28.1, 27.9, 
25.3, 24.4, 21.4, 14.4 (11 -CH2, -C(CH3)2, Me), 13.2 (-(CH2)11CH3). LSIMS m/z 563 [52 %, 
(M+Na)+]. HRLSIMS m/z found 563.3564, calc. for C31H48N4O4Na: 563.3573. Deprotection of 
this compound (49.5 mg, 0.092 mmol) was carried out in HCl (1 M):THF 1:1 (5 mL) at r.t 
overnight. Solvent was then evaporated and the residue was purified by chromatography column 
over  silica gel (CH2Cl2:MeOH, 20:1) affording the corresponding 3,4-O-unprotected derivative 
(47.6 mg, 95%). To a solution of this derivative (43.6 mg, 0.087 mmol) in MeOH (2 mL), Pd/C 
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(10%) and HCl (5 M, 70 L) were added. The mixture was hydrogenated at 1 atm for 3 h and 
then diluted with MeOH, filtered through Celite, and evaporated, to afford  31 as an amorphous 
solid (33.2 mg, 95%).  
27
Dα  -16.5 (c 0.95, MeOH).  IR νmax  3374 (OH, NH), 2920, 2851, 1636, 
1120 cm-1. 1H NMR (300 MHz, MeOD, δ ppm) δ 8.38 (s, 1H, H-5’’), 5.10-4.90 (m, 2H, H-1’a,  
H-1’b), 4.29-4.07 (m, 3H, H-2, H-3, H-4), 3.88 (m, 1H, H-5), 2.84 (br s, 2H, -CH2(CH2)11CH3), 
1.74 (br s, 2H, -CH2CH2(CH2)9CH3), 1.41-1.29 (m, 23H, CH2(CH2)10CH3, Me), 0.89 (t, 3H, JH,H 
6.6, -(CH2)11CH3). 
13C NMR (75.4 MHz, MeOD, δ ppm) δ 148.5 (C-4’’), 126.5 (C-5’’), 75.4, 
72.6, 61.2 (C-2, C-3, C-4), 59.2 (C-5), 51.8 (C-1’), 33.0, 30.7, 30.6, 30.4, 30.3, 30.1, 30.0, 25.5, 
23.6 (11 CH2), 14.4 (-(CH2)11CH3), 12.1 (Me). LSIMS m/z 367 [62 %, (M+H)
+]. HRLSIMS m/z 
found 367.3056, calc. for C20H39N4O2: 367.3073. 
 (2R,3R,4S)-2-[(4’’-dodecyl)-1H-1,2,3-triazole-1-yl)methyl)-pyrrolidine-3,4-diol 
hydrochloride (32). To a solution of 25 (75 mg, 0.23 mmol) in toluene (2 mL) were added 
tetradec-1-yne (72 μL, 0.30 mmol), DIPEA (85.1 μL, 0.83 mmol) and CuI (13 mg, 0.07 mmol). 
The mixture was stirred at r.t. for 20 h and then, a sat. aq. soln. of NaHCO3 was added and 
extracted with AcOEt. The organic phases were dried, filtered and concentrated. Purification by 
chromatography column (AcOEt:cyclohexane 1:2) afforded the corresponding triazole derivative  
(95 mg, 80%).  
27
Dα -58.6 (c 0.81, CH2Cl2).  IR νmax 2917, 2848, 1692 (C=O), 1425, 1053, 700 
cm-1. 1H NMR (300 MHz, DMSO-d6, 363 K, δ ppm) δ 7.66 (s, 1H, H-5’’), 7.37-7.28 (m, 5H, H-
arom.), 5.11 (d, 1H, 2JH, H 12.9, CH2 of Cbz), 5.01 
 (d, 1H, CH2 of Cbz), 4.72 (d, 1H, J3,4 5.7, H-
3), 4.59 (dd, 1H, J4,5 10.8, H-4), 4.54 (dd, 1H, 
2J1’a,1’b 14.1, J1a’,2 6.6, H-1’a), 4.45 (dd, 1H, J1’b,2 
5.7, H-1’b),  4.35 (t, 1H, J2,5 6.0, H-2), 3.67 (d, 1H, 
2J5a,5b 12.8, H-5a), 3.10 (dd, 1H, H-5b), 2.60 
(t, 2H, JH,H 7.4, -CH2(CH2)10CH3), 1.59 (q, 2H, JH,H 7.3, -CH2CH2(CH2)9CH3), 1.30-1.25 (m, 
24H, -CH2CH2(CH2)9CH3, -C(CH3)2), 0.87 (t, 3H, 
2JH,H 6.6, -(CH2)11CH3). 
13C NMR  (75.4 
MHz, DMSO-d6, 363 K, δ ppm) δ 153.7 (C=O), 146.8 (C-4’’), 136.4, 127.8, 127.2, 126.7 (C-
arom.), 121.9 (C-5’’), 110.6 (C(CH3)2), 81.6 (C-3), 78.1 (C-4), 65.8 (CH2 of Cbz), 63.0 (C-2), 
51.0 (C-5), 48.3 (C-1’), 30.7, 28.4, 28.2, 28.0, 27.9, 26.2, 24.4, 24.3, 21.4 (10 CH2, -C(CH3)2), 
13.2 (-(CH2)11CH3). HRLSIMS calculated for C30H46N4O4Na: 549.3417, found 549.3409 
[M+Na]+. Deprotection of this compound (80.5 mg, 0.149 mmol) as indicated for the preparation 
of 31 afforded 32 as an amorphous solid (44.4 mg, 92%).  
27
Dα +22.9 (c 0.96, MeOH).   IR νmax  
3382, 3240 (OH, NH), 2921, 2851, 1638, 1136 cm-1. 1H NMR (300 MHz, DMSO-d6, δ ppm) δ 
10.03 (br s, 1H, NH), 9.80 (br s, 1H, NH), 8.13 (s, 1H, H-5’’), 4.97 (dd, 1H, 2J1’a, 1’b 14.3, H-1’a), 
4.74 (m, 1H, H-1’b), 4.11 (m, 1H, H-4), 3.91 (m, 1H, H-3), 3.67 (m, 1H, H-2), 3.38 (m, 1H, H-
5a), 3.01 (m, 1H, H-5b), 2.59 (br t, 2H, 2JH,H 6.99, -CH2(CH2)10CH3), 1.57 (m, 2H, -
CH2CH2(CH2)9CH3), 1.23 (m, 18H, -CH2CH2(CH2)9CH3), 0.84 (m, 3H, -(CH2)11CH3. 
13C NMR 
(75.4 MHz, DMSO-d6, 363 K, δ ppm) δ 146.8 (C-4’’), 122.8 (C-5’’), 73.0 (C-3), 68.3 (C-4), 59.6 
(C-2), 49.3 (C-5), 48.2 (C-1’), 31.2, 29.0, 28.9, 28.8, 28.7, 28.6, 28.5, 24.9, 22.0 (11 CH2), 13.9 
(-(CH2)11CH3). LSIMS  m/z 353 [80%, (M+H)
+], 375 [100%, (M+Na)+].  HRLSIMS calculated 
for C19H37N4O2: 353.2917, found 353.2929 [M+H]
+. 
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(2R,3S,4R)-2-[(4’’-Dodecyl)-1H-1,2,3-triazole-1-yl)ethyl)-pyrrolidine-3,4-diol hydrochloride 
(33). Tetradec-1-yne (47 μL, 0.19 mmol), DIPEA (110 μL, 0.64 mmol) and CuI (11 mg, 0.06 
mmol) were added to a solution of 28 (60 mg, 0.173 mmol) in toluene (1.5 mL). The mixture 
was stirred at r.t. for 24 h and then, a sat. aq. soln. of NaHCO3 was added and extracted with 
AcOEt. The organic phases were dried, filtered and concentrated. Purification by 
chromatography column (AcOEt:cyclohexane 1:2) afforded the triazole derivative (76 mg, 81%). 
Deprotection of this compound (60 mg, 0.111 mmol) as indicated for the preparation of 31 
afforded 33 as an amorphous solid (81%, 2 steps).  26Dα -8.3 (c 0.73, MeOH); IR (ν cm-1)  3362 
(OH), 2923, 2852, 1636, 1126, 1048.  1H-NMR (300 MHz, MeOD, δ ppm) δ 8.34 (s, 1H, H-5’’), 
4.72 (m, 2H), 4.43 (m, 1H), 4.19 (m, 1H), 3.64 (m, 1H), 3.44 (m, 1H), 3.15 (m, 1H), 2.84 (m, 
2H), 2.63-2.46 (m, 2H, -CH2(CH2)11CH3), 1.75 (br s, 2H, -CH2CH2(CH2)9CH3), 1.34 (m, 18H, -
CH2CH2(CH2)9CH3), 0.89 (t, 3H, JH,H 5.9, -(CH2)11CH3). 
13C-NMR (75.4 MHz, MeOD, δ ppm) 
146.6 (C-4’’), 128.7 (C-5’’), 72.0, 71.6, 60.7, 51.4, 32.9, 30.6, 30.6, 30.5, 30.3, 30.2, 29.6, 28.3, 
25.1, 23.6, 14.3 (-(CH2)11CH3). CIMS m/z 367 [100%, (M+H)
+]. HRCIMS m/z found 367.3071, 
calc. for C20H39N4O2: 367.3073.  
Cell lines and culture conditions. MiaPaCa2 and PK9 pancreatic ductal adenocarcinoma cells 
were obtained from American Type Culture Collection (ATCC, Rockville, MD, U.S.A.). Cells 
were cultured in RPMI (Gibco, Paisley, United Kingdom) supplemented with 10% heat 
inactivated fetal calf serum (FCS; Amimed, BioConcept, Allschwil, Switzerland) and 1% 
penicillin/streptomycin at 37°C (BioConcept) in a humidified atmosphere of 95% air and 5% 
CO2. 
Colorimetric cell growth assays. 5 x 103 MiaPaCa2 or PK9 cells/well were plated in 96-well 
plates and allowed to adhere overnight. Thereafter, cells were incubated with or without 
compounds in a final volume of 200 μL medium for 72h. Subsequently, cell viability was 
measured with CellTiter96 Aqueous1 (Promega) according to the manufacturer’s instructions. 
Means of triplicate wells were analyzed. IC50s were estimated using GraphPad Sofware 
(GraphPad, La Jolla, CA, USA). 
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